Newborn Screening Market - Global Forecast 2026-2032

The newborn screening market is undergoing significant transformation, driven by advances in technology, evolving clinical protocols, and increased regulatory involvement. Senior stakeholders require insight into how these trends are shaping diagnostic capabilities, care delivery models, and operational strategies for scalable and compliant newborn screening programs.

Market Snapshot: Newborn Screening Market Growth and Dynamics

The Newborn Screening Market grew from USD 982.43 million in 2025 to USD 1.07 billion in 2026. It is expected to continue growing at a CAGR of 10.66%, reaching USD 1.99 billion by 2032. Persistent demand for early detection of treatable congenital conditions, coupled with rapid technological developments and expanding policy mandates, supports this robust trajectory.

Scope & Segmentation

Analytical Platforms: High Performance Liquid Chromatography, Immunoassay, Molecular Techniques (including Polymerase Chain Reaction and Sanger Sequencing), Next Generation Sequencing, and Tandem Mass Spectrometry.
Clinical Indications: Includes cystic fibrosis, endocrine disorders, hemoglobin disorders, and inborn errors of metabolism, each requiring tailored diagnostic approaches and follow-up protocols.
End Users: Clinical laboratories, hospitals and clinics, and research laboratories, each with unique workflow priorities, integration needs, and methodological requirements.
Sample Formats: Dried blood spots and serum samples, with implications for collection logistics and analytical sensitivity.
Geographic Regions: Americas (centralized public health infrastructure and private innovation), Europe/Middle East/Africa (varied regulatory approaches and capacity-building), and Asia-Pacific (government investment and domestic adaptation).

Key Takeaways: Strategic Insights for Senior Leaders

The newborn screening market sits at the convergence of public health imperatives, clinical diagnostics, and evolving laboratory technologies, demanding coordinated, high-throughput screening solutions and evidence-driven panel selection.
Technological advancements enable multiplexed, high-resolution detection for metabolic and genetic disorders, expanding the diagnostic spectrum while supporting rapid turnaround and broader panel strategies.
Regulatory and payer shifts are driving greater clarity around evidence requirements and performance metrics, increasing the need for robust clinical validation and real-world data to support reimbursement and adoption.
Effective program delivery hinges on aligning cross-functional collaboration among technology developers, clinical leaders, and policy makers to ensure system-level optimization and scalable sample logistics.
Laboratories and end users now prioritize interoperability, confirmatory testing, and integration with data systems to provide seamless longitudinal care and actionable outcomes.
Supply chain pressures, including tariffs, have prompted strategic reassessments of vendor diversification, local sourcing, and operational resilience throughout screening ecosystems.

Tariff Impact on Supply Chains and Operations

Recent changes to tariff structures across diagnostic supply chains have elevated operational risks for import-dependent reagents, instrumentation, and consumables. In response, procurement teams focus on long-term vendor relationships, supply chain resilience, and adaptive sourcing. Manufacturers and laboratories have restructured supply chains and operational models, enhancing contingency planning, quality control, and just-in-time inventory practices.

Methodology & Data Sources

This report applies a mixed-methods approach, integrating structured interviews with laboratory and clinical stakeholders, comprehensive literature reviews, and comparative technological assessments. Analytical rigor is maintained through triangulation and iterative expert validation, supporting stakeholders seeking credible and actionable intelligence.

Why This Report Matters

Enables strategic planning by linking technology investments, regulatory compliance, and supply chain management to scalable newborn screening operations.
Supports evidence-based decision-making through deep analysis of clinical workflows, analytical platforms, and region-specific adoption drivers.
Delivers actionable recommendations for program design, workforce development, and collaborative implementation frameworks across diverse care settings.

Conclusion

The newborn screening market’s trajectory is shaped by multi-dimensional shifts in technology, policy, and clinical practice. Organizations that align scientific rigor with agile operational strategies stand to drive sustainable growth and maximize early-life health impact.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Newborn Screening Market, by Technology

8.1. High Performance Liquid Chromatography
8.2. Immunoassay
8.3. Molecular Techniques
8.3.1. Polymerase Chain Reaction
8.3.2. Sanger Sequencing
8.4. Next Generation Sequencing
8.5. Tandem Mass Spectrometry

9. Newborn Screening Market, by Test Type

9.1. Cystic Fibrosis
9.2. Endocrine Disorders
9.3. Hemoglobin Disorders
9.4. Inborn Errors Of Metabolism

10. Newborn Screening Market, by Sample Type

10.1. Dried Blood Spot
10.2. Serum Sample

11. Newborn Screening Market, by End User

11.1. Diagnostic Laboratories
11.2. Hospitals And Clinics
11.3. Research Laboratories

12. Newborn Screening Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. Newborn Screening Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Newborn Screening Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States Newborn Screening Market
16. China Newborn Screening Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Abbott Laboratories
17.6. Agilent Technologies, Inc.
17.7. Bio-Rad Laboratories, Inc.
17.8. BioMérieux SA
17.9. Danaher Corporation
17.10. MP Biomedicals LLC
17.11. Novartis AG
17.12. PerkinElmer, Inc.
17.13. Shimadzu Corporation
17.14. Siemens Healthineers AG
17.15. Thermo Fisher Scientific Inc.
17.16. Trivitron Healthcare
17.17. Waters Corporation

List of Figures

FIGURE 1. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NEWBORN SCREENING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NEWBORN SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 57. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 62. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 70. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 80. EUROPE NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. EUROPE NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 82. EUROPE NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 83. EUROPE NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 84. EUROPE NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 85. EUROPE NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 88. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 89. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 90. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. AFRICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 94. AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 95. AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 96. AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 97. AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. ASEAN NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. ASEAN NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 107. ASEAN NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 108. ASEAN NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 109. ASEAN NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 110. ASEAN NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. GCC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GCC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 113. GCC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 114. GCC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 115. GCC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 116. GCC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 119. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 121. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. BRICS NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. BRICS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 125. BRICS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 126. BRICS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 127. BRICS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 128. BRICS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. G7 NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. G7 NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 131. G7 NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 132. G7 NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 133. G7 NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 134. G7 NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. NATO NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. NATO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 137. NATO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 138. NATO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 139. NATO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 140. NATO NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. UNITED STATES NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 143. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 144. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 145. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 146. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 147. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. CHINA NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 149. CHINA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 150. CHINA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 151. CHINA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 152. CHINA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 153. CHINA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Newborn Screening market report include:

Abbott Laboratories
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
BioMérieux SA
Danaher Corporation
MP Biomedicals LLC
Novartis AG
PerkinElmer, Inc.
Shimadzu Corporation
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Trivitron Healthcare
Waters Corporation

Table Information

Report Attribute	Details
No. of Pages	199
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 1.07 Billion
Forecasted Market Value ( USD ) by 2032	$ 1.99 Billion
Compound Annual Growth Rate	10.6%
Regions Covered	Global
No. of Companies Mentioned	14

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3513EUR$3,939USD£3,047GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3789EUR$4,249USD£3,286GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5136EUR$5,759USD£4,454GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6215EUR$6,969USD£5,390GBP

Market Snapshot: Newborn Screening Market Growth and Dynamics

Scope & Segmentation

Key Takeaways: Strategic Insights for Senior Leaders

Tariff Impact on Supply Chains and Operations

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Newborn Screening Market Size, Share, Trends and Forecast by Product, Technology, Test Type, and Region, 2025-2033

Newborn Screening Market Report by Product, Technology, Test Type, Countries and Company Analysis, 2025-2033

Newborn Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Newborn Screening - Global Strategic Business Report

Newborn Screening Market Size, Share & Trends Analysis Report by Product (Instruments and Reagents & Assay Kits), Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme-Based Assays, DNA Assays, Electrophoresis), Test Type and Region with Growth Forecasts, 2025-2033